These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9130691)

  • 1. Decitabine studies in chronic and acute myelogenous leukemia.
    Kantarjian HM; O'Brien SM; Estey E; Giralt S; Beran M; Rios MB; Keating M; de Vos D; Talpaz M
    Leukemia; 1997 Mar; 11 Suppl 1():S35-6. PubMed ID: 9130691
    [No Abstract]   [Full Text] [Related]  

  • 2. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Faderl S; Issa JP; Garcia-Manero G; Rios MB; Shan J; Andreeff M; Keating M; Talpaz M
    Cancer; 2003 Aug; 98(3):522-8. PubMed ID: 12879469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
    Yang AS; Doshi KD; Choi SW; Mason JB; Mannari RK; Gharybian V; Luna R; Rashid A; Shen L; Estecio MR; Kantarjian HM; Garcia-Manero G; Issa JP
    Cancer Res; 2006 May; 66(10):5495-503. PubMed ID: 16707479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.
    Kadia TM; Thomas XG; Dmoszynska A; Wierzbowska A; Minden M; Arthur C; Delaunay J; Ravandi F; Kantarjian H
    Am J Hematol; 2015 Jul; 90(7):E139-41. PubMed ID: 25858582
    [No Abstract]   [Full Text] [Related]  

  • 5. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
    Kantarjian HM; O'Brien SM; Keating M; Beran M; Estey E; Giralt S; Kornblau S; Rios MB; de Vos D; Talpaz M
    Leukemia; 1997 Oct; 11(10):1617-20. PubMed ID: 9324279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
    Sacchi S; Kantarjian HM; O'Brien S; Cortes J; Rios MB; Giles FJ; Beran M; Koller CA; Keating MJ; Talpaz M
    Cancer; 1999 Dec; 86(12):2632-41. PubMed ID: 10594858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decitabine has promising clinical activity in chronic myeloid leukemia.
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):620-1. PubMed ID: 12503205
    [No Abstract]   [Full Text] [Related]  

  • 8. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
    Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
    [No Abstract]   [Full Text] [Related]  

  • 9. Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
    Schwartsmann G; Fernandes MS; Schaan MD; Moschen M; Gerhardt LM; Di Leone L; Loitzembauer B; Kalakun L
    Leukemia; 1997 Mar; 11 Suppl 1():S28-31. PubMed ID: 9130689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia.
    Tong X; Li J; Zhou Z; Zheng D; Liu J; Su C
    Leuk Lymphoma; 2015 Jun; 56(6):1911-3. PubMed ID: 25426665
    [No Abstract]   [Full Text] [Related]  

  • 11. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
    Ganguly S; Amin M; Divine C; Aljitawi OS; Abhyankar S; McGuirk JP
    Ann Hematol; 2013 Apr; 92(4):549-50. PubMed ID: 23111661
    [No Abstract]   [Full Text] [Related]  

  • 12. Studies of decitabine with allogeneic progenitor cell transplantation.
    Giralt S; Davis M; O'Brien S; van Besien K; Champlin R; de Vos D; Kantarjian H
    Leukemia; 1997 Mar; 11 Suppl 1():S32-4. PubMed ID: 9130690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
    Issa JP; Gharibyan V; Cortes J; Jelinek J; Morris G; Verstovsek S; Talpaz M; Garcia-Manero G; Kantarjian HM
    J Clin Oncol; 2005 Jun; 23(17):3948-56. PubMed ID: 15883410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
    Bohl SR; Dolnik A; Jensen T; Lang KM; Hackanson B; Gaidzik VI; Paschka P; Knudsen S; Döhner K; Döhner H; Claus R; Lübbert M; Bullinger L
    Leuk Lymphoma; 2017 Sep; 58(9):1-4. PubMed ID: 28278722
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment.
    Yogarajah M; Montgomery N; Matson M; Blanchard L; Frank C; Gallagher S; Pepin K; Vaught L; Muluneh B; Foster MC; Zeidner JF
    Leuk Lymphoma; 2018 Dec; 59(12):3010-3012. PubMed ID: 29749763
    [No Abstract]   [Full Text] [Related]  

  • 17. Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
    Singh SN; Cao Q; Gojo I; Rapoport AP; Akpek G
    Bone Marrow Transplant; 2012 Jul; 47(7):1008-9. PubMed ID: 22080965
    [No Abstract]   [Full Text] [Related]  

  • 18. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
    Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
    Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful resolution of acute myelogenous leukemia-associated hemophagocytic lymphohistiocytosis with decitabine.
    Mulay S; Bauer F; Boruchov A; Bilgrami S
    Leuk Lymphoma; 2011 Feb; 52(2):341-3. PubMed ID: 21142783
    [No Abstract]   [Full Text] [Related]  

  • 20. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
    Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
    J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.